Drug developed by Jerusalem-based startup targets cancer cells, weakens their defenses, and activates a local response, company says; Swiss pharma firm Roche to join trials

Roche jointly sets up investment program with Israeli life-sciences VC fund aMoon, with the aim to speed up the development of new diagnostic technologies from Israel

DSP-107, developed by KAHR Medical, hopes to have dual impact: tag cancer cells, and boost activity of the immune cells that target them